Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Advanced glycation end products as environmental risk factors for the development of type 1 diabetes.

Yap FY, Kantharidis P, Coughlan MT, Slattery R, Forbes JM.

Curr Drug Targets. 2012 Apr;13(4):526-40. Review.

PMID:
22250649
2.
3.

Cardiovascular disease: what's all the AGE/RAGE about?

Barlovic DP, Thomas MC, Jandeleit-Dahm K.

Cardiovasc Hematol Disord Drug Targets. 2010 Mar;10(1):7-15. Review.

PMID:
20041839
4.
5.

The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus.

Hori O, Yan SD, Ogawa S, Kuwabara K, Matsumoto M, Stern D, Schmidt AM.

Nephrol Dial Transplant. 1996;11 Suppl 5:13-6. Review.

PMID:
9044300
6.

Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.

Tam XH, Shiu SW, Leng L, Bucala R, Betteridge DJ, Tan KC.

Clin Sci (Lond). 2011 Jan;120(2):81-9. doi: 10.1042/CS20100256.

PMID:
20726839
7.

Induction of receptor for advanced glycation end products by insufficient leptin action triggers pancreatic β-cell failure in type 2 diabetes.

Han D, Yamamoto Y, Munesue S, Motoyoshi S, Saito H, Win MT, Watanabe T, Tsuneyama K, Yamamoto H.

Genes Cells. 2013 Apr;18(4):302-14. doi: 10.1111/gtc.12036. Epub 2013 Feb 14.

8.

Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury.

Soulis T, Thallas V, Youssef S, Gilbert RE, McWilliam BG, Murray-McIntosh RP, Cooper ME.

Diabetologia. 1997 Jun;40(6):619-28.

PMID:
9222639
10.

Elevated serum levels of advanced glycation end products and their monocyte receptors in patients with type 2 diabetes.

Su XD, Li SS, Tian YQ, Zhang ZY, Zhang GZ, Wang LX.

Arch Med Res. 2011 Oct;42(7):596-601. doi: 10.1016/j.arcmed.2011.11.001. Epub 2011 Nov 17.

PMID:
22100610
11.

The AGE/RAGE axis in diabetes-accelerated atherosclerosis.

Jandeleit-Dahm K, Watson A, Soro-Paavonen A.

Clin Exp Pharmacol Physiol. 2008 Mar;35(3):329-34. doi: 10.1111/j.1440-1681.2007.04875.x. Review.

PMID:
18290873
12.

Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.

Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T.

Microvasc Res. 2008 May;76(1):52-6. doi: 10.1016/j.mvr.2007.09.004. Epub 2007 Oct 5.

PMID:
18474381
13.

Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes.

Forbes JM, Söderlund J, Yap FY, Knip M, Andrikopoulos S, Ilonen J, Simell O, Veijola R, Sourris KC, Coughlan MT, Forsblom C, Slattery R, Grey ST, Wessman M, Yamamoto H, Bierhaus A, Cooper ME, Groop PH.

Diabetologia. 2011 May;54(5):1032-42. doi: 10.1007/s00125-011-2058-z. Epub 2011 Feb 6. Erratum in: Diabetologia. 2011 Jun;54(6):1586-7.

PMID:
21298413
14.

AGE-RAGE and AGE Cross-link interaction: important players in the pathogenesis of diabetic kidney disease.

Jensen LJ, Østergaard J, Flyvbjerg A.

Horm Metab Res. 2005 Apr;37 Suppl 1:26-34. Review.

PMID:
15918107
15.

Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.

Yamagishi S, Nakamura K, Matsui T.

Curr Drug Discov Technol. 2006 Mar;3(1):83-8. Review.

PMID:
16712466
16.

Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.

Yamagishi S.

Exp Gerontol. 2011 Apr;46(4):217-24. doi: 10.1016/j.exger.2010.11.007. Epub 2010 Nov 25. Review.

PMID:
21111800
17.

Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.

Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S.

Expert Opin Investig Drugs. 2008 Jul;17(7):983-96. doi: 10.1517/13543784.17.7.983 . Review.

PMID:
18549336
18.

Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats.

Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, Schmidt AM.

J Clin Invest. 1996 Jan 1;97(1):238-43.

19.

Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.

Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Fukami K, Okuda S, Imaizumi T.

Microvasc Res. 2008 Jan;75(1):130-4. Epub 2007 May 18.

PMID:
17560613
20.

Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.

Yamagishi S.

Ther Apher Dial. 2009 Dec;13(6):534-9. doi: 10.1111/j.1744-9987.2009.00775.x. Review.

PMID:
19954478

Supplemental Content

Support Center